Toll Free: 1-888-928-9744

Atrial Fibrillation - Pipeline Review, H2 2017

Published: Aug 8, 2017 | Pages: 88 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Atrial Fibrillation - Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Atrial Fibrillation - Pipeline Review, H2 2017, provides an overview of the Atrial Fibrillation (Cardiovascular) pipeline landscape.

Atrial fibrillation is an irregular and often rapid heart rate that commonly causes poor blood flow to the body. Symptoms include decreased blood pressure, weakness, lightheadedness, confusion and chest pain. The predisposing factors include age, heart disease, high blood pressure, family history and drinking alcohol. Treatments for atrial fibrillation may include medications and surgery. 

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Atrial Fibrillation - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Atrial Fibrillation (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Atrial Fibrillation (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Atrial Fibrillation and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 3, 2, 8 and 2 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 2 and 1 molecules, respectively.

Atrial Fibrillation (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Atrial Fibrillation (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Atrial Fibrillation (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Atrial Fibrillation (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Atrial Fibrillation (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Atrial Fibrillation (Cardiovascular)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Atrial Fibrillation (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Atrial Fibrillation (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Atrial Fibrillation - Overview 6 Atrial Fibrillation - Therapeutics Development 7 Pipeline Overview 7 Pipeline by Companies 8 Pipeline by Universities/Institutes 9 Products under Development by Companies 10 Products under Development by Universities/Institutes 11 Atrial Fibrillation - Therapeutics Assessment 12 Assessment by Target 12 Assessment by Mechanism of Action 14 Assessment by Route of Administration 16 Assessment by Molecule Type 18 Atrial Fibrillation - Companies Involved in Therapeutics Development 20 Acesion Pharma Aps 20 ARCA biopharma Inc 20 Armetheon Inc 21 AstraZeneca Plc 21 Bristol-Myers Squibb Company 22 Cardiome Pharma Corp 22 Daiichi Sankyo Company Ltd 23 Dong-A Socio Holdings Co Ltd 23 Gilead Sciences Inc 24 InCarda Therapeutics Inc 24 Merck & Co Inc 25 N-Gene Research Laboratories Inc 25 Nissan Chemical Industries Ltd 26 OMEICOS Therapeutics GmbH 26 Verseon Corp 27 Atrial Fibrillation - Drug Profiles 28 AFC-1 - Drug Profile 28 BGP-15 - Drug Profile 29 BMS-919373 - Drug Profile 31 bucindolol hydrochloride - Drug Profile 32 budiodarone - Drug Profile 39 edoxaban tosylate - Drug Profile 41 flecainide acetate - Drug Profile 47 GBCA-1 - Drug Profile 49 Gene Therapy for Atrial Fibrillation - Drug Profile 50 GS-967 - Drug Profile 51 Heparin - Drug Profile 52 MK-1832 - Drug Profile 53 NIP-151 - Drug Profile 54 NYK-1112 - Drug Profile 56 OMT-28 - Drug Profile 57 Small Molecule to Block Calcium Activated Potassium Channel for Atrial Fibrillation - Drug Profile 58 Small Molecule to Block Kv1.5 for Atrial Fibrillation - Drug Profile 59 Small Molecules to Block GIRK for Atrial Fibrillation - Drug Profile 60 Small Molecules to Inhibit CaMKII for Arrhythmias and Heart Failure - Drug Profile 61 Small Molecules to Inhibit Thrombin for Cardiovascular Diseases - Drug Profile 62 vernakalant hydrochloride - Drug Profile 64 Atrial Fibrillation - Dormant Projects 69 Atrial Fibrillation - Discontinued Products 72 Atrial Fibrillation - Product Development Milestones 74 Featured News & Press Releases 74 Appendix 85 Methodology 85 Coverage 85 Secondary Research 85 Primary Research 85 Expert Panel Validation 85 Contact Us 85 Disclaimer 86
List of Tables
Number of Products under Development for Atrial Fibrillation, H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 Products under Development by Companies, H2 2017 Products under Development by Universities/Institutes, H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Atrial Fibrillation - Pipeline by Acesion Pharma Aps, H2 2017 Atrial Fibrillation - Pipeline by ARCA biopharma Inc, H2 2017 Atrial Fibrillation - Pipeline by Armetheon Inc, H2 2017 Atrial Fibrillation - Pipeline by AstraZeneca Plc, H2 2017 Atrial Fibrillation - Pipeline by Bristol-Myers Squibb Company, H2 2017 Atrial Fibrillation - Pipeline by Cardiome Pharma Corp, H2 2017 Atrial Fibrillation - Pipeline by Daiichi Sankyo Company Ltd, H2 2017 Atrial Fibrillation - Pipeline by Dong-A Socio Holdings Co Ltd, H2 2017 Atrial Fibrillation - Pipeline by Gilead Sciences Inc, H2 2017 Atrial Fibrillation - Pipeline by InCarda Therapeutics Inc, H2 2017 Atrial Fibrillation - Pipeline by Merck & Co Inc, H2 2017 Atrial Fibrillation - Pipeline by N-Gene Research Laboratories Inc, H2 2017 Atrial Fibrillation - Pipeline by Nissan Chemical Industries Ltd, H2 2017 Atrial Fibrillation - Pipeline by OMEICOS Therapeutics GmbH, H2 2017 Atrial Fibrillation - Pipeline by Verseon Corp, H2 2017 Atrial Fibrillation - Dormant Projects, H2 2017 Atrial Fibrillation - Dormant Projects, H2 2017 (Contd..1), H2 2017 Atrial Fibrillation - Dormant Projects, H2 2017 (Contd..2), H2 2017 Atrial Fibrillation - Discontinued Products, H2 2017 Atrial Fibrillation - Discontinued Products, H2 2017 (Contd..1), H2 2017


List of Figures
Number of Products under Development for Atrial Fibrillation, H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 Number of Products by Top 10 Targets, H2 2017 Number of Products by Stage and Top 10 Targets, H2 2017 Number of Products by Top 10 Mechanism of Actions, H2 2017 Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 Number of Products by Routes of Administration, H2 2017 Number of Products by Stage and Routes of Administration, H2 2017 Number of Products by Molecule Types, H2 2017 Number of Products by Stage and Molecule Types, H2 2017

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global Automated Test Equipment (ATE) market is expected to be valued at USD 4.48 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing design complexity coupled with need for effective testing is expected to drive the gl

Read More...

Global Aerial Work Platform (AWP) truck market is expected to be valued at USD 8,003.7 million by 2022, as per a new research report by Radiant Insights, Inc. Rapid infrastructure growth due to rising real estate investment is expected to drive the i

Read More...

Global geotextile market size is likely to be valued at USD 8.24 billion by 2020; as per a new research report by Radiant Insights, Inc. Increasing use in soil reinforcement activity coupled with growing application scope in road & railway developmen

Read More...

Global activated carbon market size is likely to be valued at USD 5.3 billion by 2020; as per a new research report by Radiant Insights, Inc. Increase in commercial & residential waste water treatment demand owing to escalation in water prices is ant

Read More...

Global gold nanoparticles market size is expected to reach 4.99 billion by 2020, witnessing gains at a CAGR of 24.7%. Positive outlook towards the increasing applications of nanotechnology in medical and dentistry such as drug delivery systems, nanom

Read More...
Choose License Type
Single User - US $2000
Multi User - US $4000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify